Creating a new generation of small molecule protease inhibitors

Investors Overview

Corporate Profile

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

NASDAQ | KALV (Common Stock)
$8.48-0.16 (1.85%)
Stock chart for: KALV.O. Currently trading at $8.48 with a 52 week high of $15.80 and a 52 week low of $5.48.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources

Recent News

May 31, 2018KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference

May 29, 2018KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

May 16, 2018KalVista Pharmaceuticals Recognizes HAE Day

More News

Featured Presentations

Download Documentation Corporate Presentation